This week brought major clarity on how different depression treatments affect your brain, plus surprising findings about what makes magic mushrooms work and whether psychedelics could help teens.
Researchers compared ketamine and electroconvulsive therapy (ECT) in 365 patients with treatment-resistant depression over 3 weeks:
Why this matters: This head-to-head comparison gives patients and doctors clearer data about the cognitive trade-offs between two powerful depression treatments, potentially shifting treatment decisions toward ketamine for patients concerned about memory effects.
Key Findings
🍄 Magic Mushrooms May Need Their Supporting Cast
Scientists are debating whether psilocybin alone is enough, or if other compounds in magic mushrooms make the drugs work better. Some researchers think including secondary compounds from psychedelic mushrooms could create superior medications, while others remain skeptical due to limited data.
💡 The "entourage effect" debate: whole mushrooms vs. pure psilocybin could determine the future of psychedelic medicine.
🔬 New Depression Drug Shows Promise Like Ketamine
PA-915, a new type of antidepressant that blocks stress-related brain receptors, showed rapid and long-lasting effects in mouse studies. Like ketamine, a single dose improved depression-like behaviors for 8 weeks in chronic stress models, without causing hyperlocomotion, cognitive problems, or dependency in healthy mice.
💡 Targeting stress pathways directly might offer ketamine-like benefits without the side effects.
👥 Teen Psychedelic Research Remains Virtually Nonexistent
A comprehensive review found only 3 trial registrations and 1 trial plan involving participants under 18 from 2000-2025, with none completed or published. The proposed studies would investigate MDMA or psilocybin for teens with PTSD, autism with social anxiety, or self-harm behaviors.
💡 Major evidence gap: millions of teens suffer from mental illness, but we have zero published data on psychedelic treatments for this age group.
🎯 Psilocybin Shows Dopamine Effects That Could Help Addiction
A review of 34 clinical trials found psychedelics are being tested for alcohol, cannabis, cocaine, and other substance use disorders. Brain studies in rats showed high-dose psilocybin caused sustained, mild increases in dopamine in addiction-related brain areas - potentially helping restore normal dopamine balance.
💡 Psychedelics might treat addiction by fixing the brain's reward system, not just changing consciousness.
💊 Self-Compassion Key to Psychedelic Therapy Success
Research examining positive emotional experiences during psychedelic therapy found that self-compassion plays a central role in treatment benefits. The study suggests that mystical experiences and elevated mood during sessions contribute to lasting mental health improvements.
💡 How you treat yourself emotionally during a psychedelic experience may determine how much you benefit long-term.
🧬 Multiple Sclerosis Progression Can Reverse in One-Third of Patients
Among 4,713 multiple sclerosis patients experiencing disability progression, about one-third saw improvement over a median of 2.6 years. Younger age, lower baseline disability, and high-efficacy treatments were associated with reversal of progression.
💡 MS progression isn't always permanent - younger patients on stronger treatments have the best chance of improvement.
This week's research highlights a shift toward more personalized approaches in neuropsychiatry, from choosing ketamine over ECT based on cognitive priorities, to understanding that psychedelic benefits may depend on the full spectrum of compounds and emotional states during treatment.
